Αποτελέσματα Αναζήτησης
18 Σεπ 2023 · Global campaign launches new educational video titled, “Understanding direct oral anticoagulants (DOACs) and major bleed risks: the crucial conversation to have with your doctor.”
12 Οκτ 2020 · With the goal of developing a new class of anticoagulants associated with a lower risk of bleeding than currently available agents, dozens of drugs targeting the contact system are now in development.
19 Δεκ 2022 · The evidence from available phase 2 trials suggests that unlike direct oral anticoagulants, drugs that target FXI reduce thrombosis without a dose–response for bleeding, thereby raising the potential for a more favorable benefit–risk profile.
29 Απρ 2016 · The direct oral anticoagulants (DOACs) represent a major advance in oral anticoagulant therapy and have replaced the vitamin K antagonists as the preferred treatment for many indications.
19 Μαρ 2015 · The non-vitamin K antagonist oral anticoagulants are already replacing low-molecular-weight heparin for thromboprophylaxis in patients undergoing elective hip or knee arthroplasty and replacing warfarin for stroke prevention in patients with atrial fibrillation and treatment of venous thromboembolism.
FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have the potential to be both more efficacious and safer than the currently available direct oral anticoagulants for the prevention and treatment of venous thromboembolism.
New oral anticoagulants include direct inhibitors of thrombin, factor Xa and factor IXa. Designed to provide more streamlined anticoagulation than warfarin, these agents can be given without routine coagulation monitoring.
